For research use only. Not for therapeutic Use.
Mito-apocynin (C2), an orally active mitochondria-targeted triphenylphosphonium (TPP)-based compound, is synthesized by conjugating the Apocynin moiety with a TPP + cation. Mito-apocynin (C2) exhibits antineuroinflammatory effect[1].
Mito-apocynin (C2) (3 mg/kg; p.o.; daily for 12 days) exhibits antineuroinflammatory effect[1].
| Catalog Number | I016213 |
| CAS Number | 1254044-41-1 |
| Synonyms | 2-[(4-hydroxy-3-methoxybenzoyl)amino]ethyl-triphenylphosphanium;bromide |
| Molecular Formula | C28H27BrNO3P |
| Purity | ≥95% |
| InChI | InChI=1S/C28H26NO3P.BrH/c1-32-27-21-22(17-18-26(27)30)28(31)29-19-20-33(23-11-5-2-6-12-23,24-13-7-3-8-14-24)25-15-9-4-10-16-25;/h2-18,21H,19-20H2,1H3,(H-,29,30,31);1H |
| InChIKey | VCBKDUGPZYICTB-UHFFFAOYSA-N |
| SMILES | COC1=C(C=CC(=C1)C(=O)NCC[P+](C2=CC=CC=C2)(C3=CC=CC=C3)C4=CC=CC=C4)O.[Br-] |
| Reference | [1]. Zielonka J, et al. Mitochondria-Targeted Triphenylphosphonium-Based Compounds: Syntheses, Mechanisms of Action, and Therapeutic and Diagnostic Applications. Chem Rev. 2017 Aug 9;117(15):10043-10120. |
